SELLAS Life Sciences Group, Inc.(SLS)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

SELLAS Life Sciences Group, Inc. (SLS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. SLS is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $9.3m in revenue and is scored on the micro-cap board instead. Top institutional holders of SLS by reported 13-F value include BlackRock, STATE STREET, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. SLS trades on the Nasdaq exchange and files with the SEC under CIK 1390478. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SLS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SELLAS Life Sciences Group, Inc. directly from SEC EDGAR.

Net Income

$-9.6M

SLS key financials by period

SELLAS Life Sciences Group, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202210-K$1.0M$-41.3M—
FY 202110-K$7.6M$-20.7M—
FY 202010-K$1.9M$-16.8M—
FY 201410-K/A$9.3M$-36.6M—
FY 201310-K/A$2.5M$-76.7M—

Institutions holding SLS

Institutional investors reporting a position in SELLAS Life Sciences Group, Inc. on SEC Form 13F.
InstitutionSharesValueReported
BlackRock15,070,302$222.4M2026-06-30
STATE STREET12,996,558$191.8M2026-06-30
VANGUARD CAPITAL MANAGEMENT8,226,105$121.4M2026-06-30
SUSQUEHANNA INTERNATIONAL GROUP, LLP7,157,200$105.6M2026-06-30
GEODE CAPITAL MANAGEMENT4,884,175$72.1M2026-06-30
Anson Funds Management4,500,000$66.4M2026-06-30
CITADEL ADVISORS4,346,700$64.2M2026-06-30
SUSQUEHANNA INTERNATIONAL GROUP, LLP4,189,200$61.8M2026-06-30
CITADEL ADVISORS2,258,400$33.3M2026-06-30
VANGUARD PORTFOLIO MANAGEMENT2,161,099$31.9M2026-06-30
SEC EDGAR: CIK 1390478 →
SLS

SELLAS Life Sciences Group, Inc.

SLS
NasdaqMid CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $9.3M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Net Income

Q2 2026
EDGAR

$-9.61M

EPS (Diluted)

Q2 2026
EDGAR

$-0.05

ROIC

Q2 2026
EDGAR

-30.9%

Top Institutional Holders

as of Q2 2026
$1.54B total
BlackRock, Inc.
$222.44M+23.5%
STATE STREET CORP
$191.83M+54.8%
VANGUARD CAPITAL MANAGEMENT LLC
$121.42M+9.3%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$105.64M-6.1%
GEODE CAPITAL MANAGEMENT, LLC
$72.11M+24.8%
Anson Funds Management LP
$66.42MNew
CITADEL ADVISORS LLC
$64.16M+866.4%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$61.83M-45.1%
CITADEL ADVISORS LLC
$33.33M+402.1%
VANGUARD PORTFOLIO MANAGEMENT LLC
$31.90M+47.7%

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…